![medtronic infuse lawsuit settlement amounts medtronic infuse lawsuit settlement amounts](http://www.minfirm.com/wp-content/uploads/2012/02/birth-control-150x150.jpg)
Mitchell Hamline School of Law professor emeritus Dan Kleinberger said Thursday that the order to expand the pool of potential plaintiffs could fundamentally change the legal calculus behind a potential settlement. The only plaintiffs in the suit today are the West Virginia Pipe Trades Health and Welfare Fund, the state of Hawaii’s retirement system and a German investment group called Union Asset Management Holding AG.
![medtronic infuse lawsuit settlement amounts medtronic infuse lawsuit settlement amounts](https://img.huffingtonpost.com/asset/5cd53f891f00002f009cc95e.jpeg)
About 6.5 million shares of Medtronic stock were traded daily during that period, and nearly 1,200 major institutions owned Medtronic stock in that time. District Chief Judge John Tunheim ruled that the West Virginia Pipe Trades class-action suit is limited to shareholders who bought stock between Sept. “If you don’t get a class certification, you’re done,” McDonnell said, “because it is not financially feasible to sue individually.” Brett McDonnell said the judge’s decision to certify class-action status in a securities-law case like this one was an important step for the plaintiffs.
![medtronic infuse lawsuit settlement amounts medtronic infuse lawsuit settlement amounts](https://medicalclaimlegal.com/wp-content/uploads/2017/01/phoyoyy.jpg)
“We intend to pursue a vigorous defense in this matter and will continue efforts to obtain a complete dismissal of the case,” Medtronic spokesman Eric Epperson said in an e-mailed statement. Medtronic, limits the scope of the lawsuit, and the company continues to believe the litigants’ claims are without merit. On Thursday a Medtronic spokesman noted the ruling in the latest case, West Virginia Pipe Trades Health and Welfare Fund vs. The last time a federal judge in Minnesota granted class-action status to an Infuse-related shareholder lawsuit, Medtronic and the plaintiffs quickly moved into settlement talks in 2012 that resulted in Medtronic agreeing to pay $85 million to the investors to resolve that litigation. A federal judge in Minnesota has granted a group of investors permission to pursue a class-action lawsuit against Medtronic over allegations that the med-tech company inflated its stock value by secretly paying doctors millions of dollars to conceal adverse events associated with its bone-growth product Infuse.